Nonalcoholic Steatohepatitis clinical trials
54 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Evaluating the Pharmacokinetics and Safety of Miricorilant
- Digoxin In NASH (CODIN)
- NASH AMPK Exercise Dosing (AMPED) Trial
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Estrogen Administration for the Treatment of NASH in Postmenopausal Women
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
- Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
- Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
- Fibrosis Lessens After Metabolic Surgery
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
- The Olmsted NAFLD Epidemiology Study (TONES)
- Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Rezdiffra Pregnancy and Lactation Registry
- Thermoacoustic Method for Estimating Liver Fat Fraction
- Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
- Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
- Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
- Endoscopic Ultrasound Shear Wave Elastography Study
- Androgens and NAFLD Longitudinal Cohort Study
- Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
- Comparison of ALD, NASH, and Healthy Control Patients
- Blood Collection Biorepository for Liver Disease Research
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- Bicalutamide Therapy in Young Women With NAFLD and PCOS
- Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
- Nutrition Intervention Combined With Resmetirom for MASH
- Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
- Fibrinogen in Liver Transplant
- Isocaloric Navy-Bean Substitution in Adults With MASLD
- A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
- Guerbet Liver Fibrosis
- Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
- Physiologic and Functional Adaptations of Insulin Sensitive Tissues
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Nonalcoholic Steatohepatitis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.